Ooi, Liqing Zhuang, et al
pylori-related mucosal injury: Oral administration preferred capsules or solution, taken on an empty stomach Typical range: 250500 mcg/day in divided doses Cycle length: 46 weeks , may extend to 812 weeks for chronic conditions Some practitioners use SubQ in parallel for systemic anti-inflammatory support Potential Problems and Contraindications BPC-157 has a favorable safety profile in animal studies remarkably, no lethal dose (LD50) has been established in rodents even at extremely high doses
Oral delivery routes BPC-157 through digestion
Younger patients and those with untreated depression appear at slightly elevated risk, though absolute numbers remain low
These positive effects of kisspeptin are seen when given in vivo to cows or sheep (389), but so far have not been seen when given intravenously in small studies in human volunteers (390), although this may be because the GH stimulatory effects are only observed with central administration
Her resume is that of an experienced and intelligent judge